Oncolytics Biotech
Update in progressONCY (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing oncology treatments. It advances pelareorep, an intravenously delivered immunotherapeutic agent for gastrointestinal tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. The company collaborates with Roche to supply the immune checkpoint inhibitor atezolizumab for ongoing sponsored studies. Founded in 1998, it is based in San Diego, California.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section